Stay updated on Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial
Sign up to get notified when there's something new on the Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial page.

Latest updates to the Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe site revision was updated to v3.6.6, representing a newer version of the ClinicalTrials.gov interface. This change likely includes minor fixes or improvements and does not alter the study content displayed on the page.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5 on the page's history, indicating a minor maintenance update to the page documentation. The change does not alter study content or user-facing information.SummaryDifference0.0%

- Check46 days agoChange DetectedThe page shows a new revision tag, updating from v3.6.3 to v3.6.4, indicating a minor version update. There are no evident changes to the study details or user-facing content beyond the revision metadata.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing v3.6.2, signaling a minor platform update; study content remains unchanged.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page shows a revision tag update from v3.6.0 to v3.6.2, indicating a minor update to the site template or codebase rather than changes to the study details.SummaryDifference0.0%

- Check89 days agoChange DetectedRecruitment has ended, as the page now states no longer looking for participants. The update also adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment header along with a revision note for version 3.6.0.SummaryDifference0.3%

Stay in the know with updates to Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial page.